New spinal injection aims to slow Early-Onset Alzheimer's
NCT ID NCT05231785
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This early-stage study is testing a new drug called ALN-APP for people with early-onset Alzheimer's disease. The drug is given as a shot into the spine to see if it is safe and how it affects the body. About 60 adults with mild memory problems or mild dementia will take part. The goal is to find a safe dose and measure changes in brain-related proteins.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ONSET ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
COMPLETEDLa Jolla, California, 92037, United States
-
Clinical Trial Site
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Clinical Trial Site
RECRUITINGMontreal, H3A 2B4, Canada
-
Clinical Trial Site
RECRUITINGToronto, M3B 2S7, Canada
-
Clinical Trial Site
RECRUITINGAmsterdam, 1081 BT, Netherlands
-
Clinical Trial Site
COMPLETEDGroningen, 9713 GG, Netherlands
-
Clinical Trial Site
RECRUITINGHuntley Street, WC1E 6AG, United Kingdom
-
Clinical Trial Site
RECRUITINGSheffield, S10 2JF, United Kingdom
Conditions
Explore the condition pages connected to this study.